Kulvinder Kochar Kaur1*, Gautam Allahbadia2 and Mandeep Singh3
1Scientific Director, Dr Kulvinder Kaur Centre for Human Reproduction, Jalandhar, Punjab, India
2Scientific Director, Rotunda-A Centre for Human Reproduction, Mumbai, India
3Consultant Neurologist, Swami Satyan and Hospital, Jalandhar, Punjab, India
*Corresponding Author: Kulvinder Kochar Kaur, Scientific Director, Dr Kulvinder Kaur Centre for Human Reproduction, Jalandhar, Punjab, India.
Received: October 31, 2020; Published: February 10, 2021
Earlier having reviewed structure and treatment (Figure 1) options of COVID-19 secondary to SARS-COV2 [1-5], still the pandemic instead of getting controlled is on a rise and urgent need of a vaccine is required with the 3rd wave having attacked the world, here we discuss important points regards to getting insight of disease pathogenesis along with advantage of bridge therapies, like hyperimmune globulin along with convalescent human plasma besides developing vaccines, antivirals and monoclonal abs. Just 11 months back knowledge was not there. Here we sum up phase 3 trial of vaccines-status.
Citation: Kulvinder Kochar Kaur., et al. “Are We Any Closer for a Safe Vaccine to be Launched-Experience of Phase 3 Trials of Certain Vaccines with Immune Responses in COVID-19 with a 3rs Wave in Most Countries Escalating SARS-CoV2-Patients". Acta Scientific Microbiology 4.3 (2021): 30-36.
Copyright: © 2020 Kulvinder Kochar Kaur., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.